Urologix seeks US OK for ThermoCath BPH (benign prostatic hyperplasia) therapy:
This article was originally published in Clinica
Executive Summary
Urologix has filed an application with the US FDA for approval to market its minimally invasive Cooled ThermoCath system for treating benign prostatic hyperplasia (BPH). The device uses targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort, says the Minneapolis, Minnesota firm. Urologix adds that pending US approval, it anticipates launching the product in the autumn this year.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.